|
|
Post by boytroy88 on Oct 27, 2015 22:01:59 GMT -5
|
|
|
|
Post by rrtzmd on Oct 28, 2015 0:28:21 GMT -5
New ticker symbol: מנקד Can someone post a link to a real time MNKD quote on the TASE? I want to start getting up at 2am to check quotes instead of waiting until 0930 every day Just posted this on ST also. If you bring it up (in English) for BTX now, and then switch the security/company/symbol selection to MNKD when it starts, you'll get real time data, historical charts, etc etc. Its not up yet to select. Here is a direct link to the BTX page: www.tase.co.il/Eng/General/Company/Pages/companyMainData.aspx?ShareID=01136365&CompanyID=001651&subDataType=0&Just been taking the platform for a little test drive. Useful stuff there! Curious to see though, if the real time data will be posted in $US or not ... This is the MNKD page: MNKD trading |
|
|
|
Post by hawaiiguy42 on Oct 28, 2015 1:22:04 GMT -5
|
|
|
|
Post by kball on Oct 28, 2015 5:51:59 GMT -5
New ticker symbol: מנקדCan someone post a link to a real time MNKD quote on the TASE? I want to start getting up at 2am to check quotes instead of waiting until 0930 every day Makes a pretty good Dreidel too btw |
|
|
|
Post by sla55 on Oct 29, 2015 18:27:08 GMT -5
www.mondovisione.com/media-and-resources/news/tel-aviv-stock-exchange-opening-bell-ceremony-with-mannkind-corporation/Date 29/10/2015 Yesterday morning, (28.10.15), MannKind Corporation celebrated its Dual Listing at the Tel Aviv Stock Exchange by taking part in the "Opening Bell Ceremony". MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. Our only approved product, AFREZZA, (insulin human [rDNA origin]) inhalation powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration on June 27, 2014 to improve glycemic control in adult patients with diabetes. Yossi Beinart, TASE CEO said: "Israel as a Start Up Nation, is the home of Technology and Biomed Industries and The Tel Aviv Stock Exchange make various steps to encourage public companies in this sector. MannKind Corporation has a long lasting Israeli relationship along with Mr. Alfred Mann, ( Founder and Chief Executive of MannKind), who stands behind some of the Israeli breakthrough's in the medical device developements. I hope and believe that Mannkind Corporation's dual listing is another step in its relations with Israel and the Israeli Biomed community, which will broaden their presence here". Matthew Pepper, Vice president and CFO of MannKind, who took the stage and rang the TASE opening bell added, "I am proud and excited to be in Israel to list Mannkind for trade on the TASE. This is the first step of the company in Israel which reflects our intention to maintain a long term relationship with the Israeli capital market and the local biomedical industry. MannKind managed to promote a product throughout all stages of development to marketing approval and to market. Our ability to deliver insulin through an inhaler involves a revolutionary technology and I hope that our collaboration with Sanofi will help the inhaler also enter the Israeli hospitals soon. We are going to continue to develop the unique technology also for additional medical indications. " Attachment Deleted From right to left: Drorit Vilnai, Head of Listing Unit; Amnon Mandelbaum, Senior Managing Director at Sunrise Securities; Avigail Shenhav-Tal, Senior Manager in the Listing Unit; Yossi Beinart, CEO of the TASE; Matthew J. Pfeffer, Vice President and Chief Financial Officer of MannKind ; Amnon Neubach, Chairman of the Board of TASE. Photo: Kobi Kantor
|
|
|
|
Post by kball on Oct 29, 2015 19:21:37 GMT -5
www.mondovisione.com/media-and-resources/news/tel-aviv-stock-exchange-opening-bell-ceremony-with-mannkind-corporation/-snip- Matthew Pepper, Vice president and CFO of MannKind, who took the stage and rang the TASE opening bell added, "I am proud and excited to be in Israel to list Mannkind for trade on the TASE. This is the first step of the company in Israel which reflects our intention to maintain a long term relationship with the Israeli capital market and the local biomedical industry. MannKind managed to promote a product throughout all stages of development to marketing approval and to market. Our ability to deliver insulin through an inhaler involves a revolutionary technology and I hope that our collaboration with Sanofi will help the inhaler also enter the Israeli hospitals soon. We are going to continue to develop the unique technology also for additional medical indications. " From right to left: Drorit Vilnai, Head of Listing Unit; Amnon Mandelbaum, Senior Managing Director at Sunrise Securities; Avigail Shenhav-Tal, Senior Manager in the Listing Unit; Yossi Beinart, CEO of the TASE; Matthew J. Pfeffer, Vice President and Chief Financial Officer of MannKind ; Amnon Neubach, Chairman of the Board of TASE. Photo: Kobi Kantor Matt crossing his fingers and hoping, or towing the implied company policy of not disclosing material events per partnership agreements? |
|
|
|
Post by mnholdem on Oct 29, 2015 19:41:01 GMT -5
Was MannKind's CEO simply too busy to be there? Perhaps he was in France or meeting with other important people.
|
|
|
|
Post by tchalaa on Oct 30, 2015 8:43:43 GMT -5
On Nov 11, 2015 we will know the percentage of total shares moving over to TASE passive Investors, reducing at the same time the free float for retailers ![]() ![]() Attachment Deleted |
|
